Literature DB >> 24702614

Long-term incidence and risk factors for development of spinal deformity following resection of pediatric intramedullary spinal cord tumors.

Raheel Ahmed1, Arnold H Menezes, Olatilewa O Awe, Kelly B Mahaney, James C Torner, Stuart L Weinstein.   

Abstract

OBJECT: Spinal deformity in pediatric patients with intramedullary spinal cord tumors (IMSCTs) may be either due to neurogenic disability or due to secondary effects of spinal decompression. It is associated with functional decline and impairment in health-related quality-of-life measures. The authors sought to identify the long-term incidence of spinal deformity in individuals who had undergone surgery for IMSCTs as pediatric patients and the risk factors and overall outcomes in this population.
METHODS: Treatment records for pediatric patients (age < 21 years) who underwent surgical treatment for histology-proven primary IMSCTs between 1975 and 2010 were reviewed. All patients were evaluated in consultation with the pediatric orthopedics service. Clinical records were reviewed for baseline and follow-up imaging studies, surgical fusion treatment, and long-term skeletal and disease outcomes.
RESULTS: The authors identified 55 patients (30 males and 25 females) who were treated for pediatric IMSCTs between January 1975 and January 2010. The mean duration of follow-up (± SEM) was 11.4 ± 1.3 years (median 9.3 years, range 0.2-37.2 years). Preoperative skeletal deformity was diagnosed in 11 (20%) of the 55 patients, and new-onset postoperative deformity was noted in 9 (16%). Conservative management with observation or external bracing was sufficient in 8 (40%) of these 20 cases. Surgical fusion was necessary in 11 (55%). Posterior surgical fusion was sufficient in 6 (55%) of these 11 cases, while combined anterior and posterior fusion was undertaken in 5 (45%). Univariate and multivariate analysis of clinical and surgical treatment variables indicated that preoperative kyphoscoliosis (p = 0.0032) and laminectomy/laminoplasty at more than 4 levels (p = 0.05) were independently associated with development of spinal deformity that necessitated surgical fusion. Functional scores and 10-year disease survival outcomes were similar between the 2 groups.
CONCLUSIONS: Long-term follow-up is essential to monitor for delayed development of spinal deformity, and regular surveillance imaging is recommended for patients with underlying deformity. The authors' extended follow-up highlights the risk factors associated with development of spinal deformity in patients treated for pediatric IMSCTs. Surgical fusion allows patients who develop progressive deformity to achieve long-term functional and survival outcomes comparable to those of patients who do not develop progressive deformity.

Entities:  

Keywords:  IMSCT = intramedullary spinal cord tumor; XRT = radiation therapy; fusion; intramedullary tumors; laminoplasty; oncology; spinal deformity; spine

Mesh:

Year:  2014        PMID: 24702614     DOI: 10.3171/2014.1.PEDS13317

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  14 in total

Review 1.  Syringomyelia following surgery for a spontaneous spinal subdural hematoma in a 13-year-old girl with congenital von Willebrand disease: case report and literature review.

Authors:  A Ben Nsir; A Boubaker; H Jemel
Journal:  Childs Nerv Syst       Date:  2015-08-16       Impact factor: 1.475

2.  Pediatric intramedullary spinal cord tumor outcomes using the WeeFIM scale.

Authors:  Thomas Noh; Manuel S Vogt; David W Pruitt; Trent R Hummel; Francesco T Mangano
Journal:  Childs Nerv Syst       Date:  2018-05-25       Impact factor: 1.475

3.  An Analysis of Clinical Efficacy of Microsurgical Resection of Intradural Neoplasm by Unilateral Approach with Caspar Retractors.

Authors:  Xuan Wang; Hong-Yang Zhao; De-Qiang Lei; Wen-De Zhu; Ying-Chun Zhou
Journal:  Med Princ Pract       Date:  2019-09-20       Impact factor: 1.927

Review 4.  Treatment patterns of children with spine and spinal cord tumors: national outcomes and review of the literature.

Authors:  Faris Shweikeh; Carolyn Quinsey; Roger Murayi; Ryan Randle; Miriam Nuño; Mark D Krieger; J Patrick Johnson
Journal:  Childs Nerv Syst       Date:  2017-05-08       Impact factor: 1.475

5.  Evaluating pediatric spinal low-grade gliomas: a 30-year retrospective analysis.

Authors:  Steven S Carey; Zsila Sadighi; Shengjie Wu; Jason Chiang; Giles W Robinson; Yahya Ghazwani; Anthony P Y Liu; Sahaja Acharya; Thomas E Merchant; Frederick A Boop; Amar Gajjar; Ibrahim Qaddoumi
Journal:  J Neurooncol       Date:  2019-10-22       Impact factor: 4.130

6.  Spinal meningioma and factors predictive of post-operative deterioration.

Authors:  Vianney Gilard; Alice Goia; François-Xavier Ferracci; Florent Marguet; Nicolas Magne; Olivier Langlois; Alexis Perez; Stéphane Derrey
Journal:  J Neurooncol       Date:  2018-06-20       Impact factor: 4.130

7.  Pediatric Holocord Epidural Abscess Treated with Apical Laminotomies with Catheter-directed Irrigation and Drainage.

Authors:  Elena Kurudza; James A Stadler
Journal:  Cureus       Date:  2019-09-23

8.  Surgical management of intradural spinal cord tumors in children and young adults: A single-center experience with 50 patients.

Authors:  Neriman Özkan; Ramazan Jabbarli; Karsten Henning Wrede; Zeynep Sariaslan; Klaus Peter Stein; Philipp Dammann; Adrian Ringelstein; Ulrich Sure; Erol Ibrahim Sandalcioglu
Journal:  Surg Neurol Int       Date:  2015-12-08

Review 9.  Pediatric intramedullary schwannoma with syringomyelia: a case report and literature review.

Authors:  Keda Wang; Jizong Zhao; Yan Zhang; Yibing Su
Journal:  BMC Pediatr       Date:  2018-11-28       Impact factor: 2.125

10.  Risk factor analysis for progressive spinal deformity after resection of intracanal tumors─ a retrospective study of 272 cases.

Authors:  Pangbo Wang; Kang Ma; Tunan Chen; Xingsen Xue; Dada Ma; Shi Wang; Xin Chen; Hui Meng; Gaoyu Cui; Boyuan Gao; Jiangkai Lin; Hua Feng; Weihua Chu
Journal:  BMC Neurol       Date:  2020-01-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.